Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-05 · accession 0001193125-26-004641 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-06 | 2026-01-05 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $32.07 | +3,118 | 666.2K | +0.5% | +$100.0K |
| D | 2026-01-06 | 2026-01-05 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $0.00 | -3,118 | 446.9K | -0.7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-05 | M | A | 3,118 | $32.07 | 666,195 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-01-05 | M | D | 3,118 | $0.00 | 446,882 | D | $32.07 · — to 2033-03-01 | 3,118 Common Stock | (F1) The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. |